{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"9.4","value":"7.6"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"10.4","value":"6.6"},{"groupId":"OG002","lowerLimit":"5.4","upperLimit":"7.4","value":"6.0"},{"groupId":"OG003","lowerLimit":"4.0","upperLimit":"8.1","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"33"}],"units":"Participants"}],"description":"Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.\n\nProgressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG000","title":"Wild-type KRAS - Panitumumab Plus FOLFIRI"},{"description":"Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG001","title":"Wild-type KRAS - FOLFIRI Alone"},{"description":"Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG002","title":"Mutant KRAS - Panitumumab Plus FOLFIRI"},{"description":"Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG003","title":"Mutant KRAS - FOLFIRI Alone"}],"paramType":"MEDIAN","populationDescription":"KRAS Central Tumor Response Analysis Set: Responders","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}